A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Salvage Treatment with Lenalidomide and Dexamethasone in Patients with Relapsed Refractory Mantle Cell Lymphoma.
Francesco Zaja,Stefano De Luca,Umberto Vitolo,Lorella Orsucci,Alessandro Levis,Flavia Salvi,Livio Gargantini,Erika Ravelli,Alessandra Tucci,Chiara Bottelli,Monica Balzarotti,Armando Santoro,Ercole Brusamolino,Maurizio Bonfichi,Alice Di Rocco,Caterina Stelitano,Luca Baldini,Stefano Pileri,Stefano Volpetti,Giovannino Ciccone,Antonella Ferranti,Renato Fanin +21 more
TL;DR: Initial results from this study confirm the high therapeutic activity of Len in patients with relapsed and refractory MCL and explore changes in tumour biomarkers relative to response to treatment with Len Dex.
Journal ArticleDOI
High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin lymphoma.
Massimo Magagnoli,Monica Balzarotti,Licia Siracusano,Michele Spina,Luciano Isa,Emanuela Morenghi,Umberto Tirelli,Armando Santoro +7 more
TL;DR: A pilot study with a brief chemotherapy course, consisting of two cycles of a modified ABVD regimen (VEBEP) followed by IFRT in early-stage Hodgkin lymphoma, using patients with newly diagnosed stage I or II HL according to the Ann Arbor criteria.
Journal ArticleDOI
Pd18-04 a phase 1 safety study of oncofid-p-b administered for 12 consecutive weeks in bcg unresponsive/intolerant patients with bladder carcinoma in situ (cis): preliminary results
Rodolfo Hurle,Massimo Lazzeri,Giorgio Guazzoni,Piergiuseppe Colombo,Armando Santoro,Ottavio De Cobelli,Ettore Di Trapani,Gloria Nohales,Llorente Carlos,Ramon Duran-Merino +9 more
TL;DR: P-HA is very well tolerated when administered for up to 12 consecutive weeks, with no drug related AEs and no study withdrawal, and the excellent tolerability for a prolonged treatment schedule coupled with the good clinical results support its further clinical development.
Journal ArticleDOI
Single-cell profiling reveals the dynamics of cytomegalovirus-specific T cells in haploidentical hematopoietic stem cell transplantation.
Jasper J. P. van Beek,Simone Puccio,Alessandra Roberto,Federica De Paoli,Giulia Graziano,Elisa Salviato,Giorgia Alvisi,Veronica Zanon,Alice Scarpa,Elisa Zaghi,Michela Calvi,Clara Di Vito,Rossana Mineri,Barbara Sarina,Chiara De Philippis,Armando Santoro,Jacopo Mariotti,Stefania Bramanti,Francesco Ferrari,Luca Castagna,Domenico Mavilio,Enrico Lugli +21 more
Journal ArticleDOI
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors.
Paolo Andrea Zucali,Matteo Simonelli,F. De Vincenzo,Elena Lorenzi,Lorenza Rimassa,Luca Balzarini,Vittorio Quagliuolo,Antonio Lambiase,Claudio Bordignon,Armando Santoro +9 more
TL;DR: NGR-hTNF can be safely escalated at doses higher than MTD and induces low shedding of receptors and early antivascular effects and reduces tumor vascularity and volume transfer coefficient by dynamic contrast enhanced magnetic resonance imaging.